Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.

• Post author:jaimeuss_admin
• Post published:2 בOctober 2018
• Post category:Research

Continue ReadingKadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.

Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.

• Post author:jaimeuss_admin
• Post published:2 בOctober 2018
• Post category:Research

Continue ReadingCellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

• Post author:jaimeuss_admin
• Post published:16 בSeptember 2018
• Post category:Research

Continue ReadingKadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged

• Post author:jaimeuss_admin
• Post published:30 בAugust 2018
• Post category:Research

Continue ReadingCellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged

Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9

• Post author:jaimeuss_admin
• Post published:30 בAugust 2018
• Post category:Research

Continue ReadingCellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9

Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.

• Post author:jaimeuss_admin
• Post published:30 בAugust 2018
• Post category:Research

Continue ReadingCellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.

Cellect Biotechnology Ltd.: Exposure to the global stem cells industry

• Post author:jaimeuss_admin
• Post published:30 בAugust 2018
• Post category:Research

Continue ReadingCellect Biotechnology Ltd.: Exposure to the global stem cells industry